通用对照液播种扩增试验:α-突触核蛋白病的标准化检测。

IF 2.6 3区 综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES
PLoS ONE Pub Date : 2025-06-25 eCollection Date: 2025-01-01 DOI:10.1371/journal.pone.0326568
Remarh Bsoul, Anja H Simonsen, Kristian S Frederiksen, Kirsten Svenstrup, Sara Bech, Lisette Salvesen, Anne-Mette Hejl, Marcello Rossi, Piero Parchi, Eva L Lund, Aušrinė Areškevičiūtė
{"title":"通用对照液播种扩增试验:α-突触核蛋白病的标准化检测。","authors":"Remarh Bsoul, Anja H Simonsen, Kristian S Frederiksen, Kirsten Svenstrup, Sara Bech, Lisette Salvesen, Anne-Mette Hejl, Marcello Rossi, Piero Parchi, Eva L Lund, Aušrinė Areškevičiūtė","doi":"10.1371/journal.pone.0326568","DOIUrl":null,"url":null,"abstract":"<p><p>Seeding amplification assays, specifically the Real-Time Quaking-Induced Conversion method (RT-QuIC), have shown great diagnostic potential for α-synucleinopathies. Numerous research groups have demonstrated the method's high sensitivity and specificity using cerebrospinal fluid (CSF) samples and various RT-QuIC workflows. However, establishing a uniform and stably performing RT-QuIC protocol remains challenging. To address this, we established an RT-QuIC protocol with a Universal Control Fluid (UCF), which is simple to adopt, performs stably, and allows uniform preparation of both sample and control reactions. Firstly, we adapted and established a published 48-hour RT-QuIC protocol, including the in-house production of recombinant α-synuclein (rec α-syn), and evaluated its sensitivity and specificity through a blinded screening of an 81 CSF sample cohort consisting of Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease, motor neuron disease, multiple system atrophy, unidentified neurodegenerative diseases, and healthy controls. Additionally, we tested all CSF samples in three volumes to determine which volume provides the best diagnostic accuracy. The established RT-QuIC performs nearly equally well with 7 µL and 15 µL added CSF, resulting in 94% and 94.5% diagnostic accuracy, respectively. Secondly, we developed a UCF solution and tested its performance with the established RT-QuIC protocol. Results indicate that UCF, used in defined volume and concentration, standardizes the preparation of both sample and control reactions without compromising the assay's diagnostic accuracy and provides a stabilizing environment for the reactions, ensuring higher reproducibility. The established RT-QuIC protocol for pathologic α-synuclein detection in PD and DLB CSF samples is highly sensitive (92-96%) and specific (93-96%). Therefore, it is important that its adoption in clinical laboratories is uncomplicated and uniform. RT-QuIC with UCF simplifies, standardizes, and stabilizes the assay's performance and, thus, could be recommended as a standard protocol for accurate detection of α-synucleinopathies.</p>","PeriodicalId":20189,"journal":{"name":"PLoS ONE","volume":"20 6","pages":"e0326568"},"PeriodicalIF":2.6000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194165/pdf/","citationCount":"0","resultStr":"{\"title\":\"Seeding amplification assay with Universal Control Fluid: Standardized detection of α-synucleinopathies.\",\"authors\":\"Remarh Bsoul, Anja H Simonsen, Kristian S Frederiksen, Kirsten Svenstrup, Sara Bech, Lisette Salvesen, Anne-Mette Hejl, Marcello Rossi, Piero Parchi, Eva L Lund, Aušrinė Areškevičiūtė\",\"doi\":\"10.1371/journal.pone.0326568\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Seeding amplification assays, specifically the Real-Time Quaking-Induced Conversion method (RT-QuIC), have shown great diagnostic potential for α-synucleinopathies. Numerous research groups have demonstrated the method's high sensitivity and specificity using cerebrospinal fluid (CSF) samples and various RT-QuIC workflows. However, establishing a uniform and stably performing RT-QuIC protocol remains challenging. To address this, we established an RT-QuIC protocol with a Universal Control Fluid (UCF), which is simple to adopt, performs stably, and allows uniform preparation of both sample and control reactions. Firstly, we adapted and established a published 48-hour RT-QuIC protocol, including the in-house production of recombinant α-synuclein (rec α-syn), and evaluated its sensitivity and specificity through a blinded screening of an 81 CSF sample cohort consisting of Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease, motor neuron disease, multiple system atrophy, unidentified neurodegenerative diseases, and healthy controls. Additionally, we tested all CSF samples in three volumes to determine which volume provides the best diagnostic accuracy. The established RT-QuIC performs nearly equally well with 7 µL and 15 µL added CSF, resulting in 94% and 94.5% diagnostic accuracy, respectively. Secondly, we developed a UCF solution and tested its performance with the established RT-QuIC protocol. Results indicate that UCF, used in defined volume and concentration, standardizes the preparation of both sample and control reactions without compromising the assay's diagnostic accuracy and provides a stabilizing environment for the reactions, ensuring higher reproducibility. The established RT-QuIC protocol for pathologic α-synuclein detection in PD and DLB CSF samples is highly sensitive (92-96%) and specific (93-96%). Therefore, it is important that its adoption in clinical laboratories is uncomplicated and uniform. RT-QuIC with UCF simplifies, standardizes, and stabilizes the assay's performance and, thus, could be recommended as a standard protocol for accurate detection of α-synucleinopathies.</p>\",\"PeriodicalId\":20189,\"journal\":{\"name\":\"PLoS ONE\",\"volume\":\"20 6\",\"pages\":\"e0326568\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-06-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194165/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PLoS ONE\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://doi.org/10.1371/journal.pone.0326568\",\"RegionNum\":3,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PLoS ONE","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1371/journal.pone.0326568","RegionNum":3,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

种子扩增试验,特别是实时地震诱导转化法(RT-QuIC),已经显示出对α-突触核蛋白病的巨大诊断潜力。许多研究小组已经使用脑脊液(CSF)样本和各种RT-QuIC工作流程证明了该方法的高灵敏度和特异性。然而,建立一个统一的、稳定运行的RT-QuIC协议仍然是一个挑战。为了解决这个问题,我们建立了一个带有通用控制流体(UCF)的RT-QuIC协议,该协议易于采用,性能稳定,并且允许样品和对照反应的均匀制备。首先,我们调整并建立了已发表的48小时RT-QuIC方案,包括内部生产重组α-突触核蛋白(rec α-syn),并通过盲法筛选81个脑脊液样本队列,包括帕金森病(PD)、路易体痴呆(DLB)、阿尔茨海默病、运动神经元病、多系统萎缩、未知神经退行性疾病和健康对照,评估其敏感性和特异性。此外,我们测试了所有脑脊液样本的三体积,以确定哪一体积提供最好的诊断准确性。建立的RT-QuIC在添加7µL和15µL CSF时表现几乎相同,分别达到94%和94.5%的诊断准确率。其次,我们开发了一个UCF解决方案,并使用已建立的RT-QuIC协议测试了其性能。结果表明,在规定的体积和浓度下使用UCF,可以标准化样品和对照反应的制备,而不会影响检测的诊断准确性,并为反应提供稳定的环境,确保更高的再现性。建立的RT-QuIC方案对PD和DLB脑脊液样品的病理性α-突触核蛋白检测具有高度的敏感性(92-96%)和特异性(93-96%)。因此,重要的是在临床实验室的采用是简单和统一的。具有UCF的RT-QuIC简化、标准化和稳定了分析的性能,因此可以推荐作为准确检测α-突触核蛋白病的标准方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Seeding amplification assay with Universal Control Fluid: Standardized detection of α-synucleinopathies.

Seeding amplification assay with Universal Control Fluid: Standardized detection of α-synucleinopathies.

Seeding amplification assay with Universal Control Fluid: Standardized detection of α-synucleinopathies.

Seeding amplification assay with Universal Control Fluid: Standardized detection of α-synucleinopathies.

Seeding amplification assays, specifically the Real-Time Quaking-Induced Conversion method (RT-QuIC), have shown great diagnostic potential for α-synucleinopathies. Numerous research groups have demonstrated the method's high sensitivity and specificity using cerebrospinal fluid (CSF) samples and various RT-QuIC workflows. However, establishing a uniform and stably performing RT-QuIC protocol remains challenging. To address this, we established an RT-QuIC protocol with a Universal Control Fluid (UCF), which is simple to adopt, performs stably, and allows uniform preparation of both sample and control reactions. Firstly, we adapted and established a published 48-hour RT-QuIC protocol, including the in-house production of recombinant α-synuclein (rec α-syn), and evaluated its sensitivity and specificity through a blinded screening of an 81 CSF sample cohort consisting of Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease, motor neuron disease, multiple system atrophy, unidentified neurodegenerative diseases, and healthy controls. Additionally, we tested all CSF samples in three volumes to determine which volume provides the best diagnostic accuracy. The established RT-QuIC performs nearly equally well with 7 µL and 15 µL added CSF, resulting in 94% and 94.5% diagnostic accuracy, respectively. Secondly, we developed a UCF solution and tested its performance with the established RT-QuIC protocol. Results indicate that UCF, used in defined volume and concentration, standardizes the preparation of both sample and control reactions without compromising the assay's diagnostic accuracy and provides a stabilizing environment for the reactions, ensuring higher reproducibility. The established RT-QuIC protocol for pathologic α-synuclein detection in PD and DLB CSF samples is highly sensitive (92-96%) and specific (93-96%). Therefore, it is important that its adoption in clinical laboratories is uncomplicated and uniform. RT-QuIC with UCF simplifies, standardizes, and stabilizes the assay's performance and, thus, could be recommended as a standard protocol for accurate detection of α-synucleinopathies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
PLoS ONE
PLoS ONE 生物-生物学
CiteScore
6.20
自引率
5.40%
发文量
14242
审稿时长
3.7 months
期刊介绍: PLOS ONE is an international, peer-reviewed, open-access, online publication. PLOS ONE welcomes reports on primary research from any scientific discipline. It provides: * Open-access—freely accessible online, authors retain copyright * Fast publication times * Peer review by expert, practicing researchers * Post-publication tools to indicate quality and impact * Community-based dialogue on articles * Worldwide media coverage
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信